HK Stock Market Move | The beauty and cosmetics sector experienced the highest increase, with a double-digit growth in the 618 beauty market. Institutions predict that the beauty industry will continue to grow at a slow pace in the second quarter.
The beauty and cosmetics sector is leading the gains, as of the time of publication, Lin Qingxuan (02657) rose by 8.05% to 47.8 Hong Kong dollars; Juzi Biotech (02367) rose by 5.5% to 28.38 Hong Kong dollars; Shangmei Shares (02145) rose by 4.9% to 27.38 Hong Kong dollars; Maogeping (01318) rose by 4.16% to 53.95 Hong Kong dollars.
In the beauty and makeup sector, as of the time of publication, FOREST CABIN (02657) rose by 8.05% to 47.8 Hong Kong dollars; GIANT BIOGENE (02367) rose by 5.5% to 28.38 Hong Kong dollars; CHICMAX (02145) rose by 4.9% to 27.38 Hong Kong dollars; MAO GEPING (01318) rose by 4.16% to 53.95 Hong Kong dollars.
In terms of news, according to Analysys, during the 618 period, the turnover of major platforms in the beauty and makeup sector increased by 11.4% year-on-year. Guotai Junan Securities pointed out that during the 618 period, the online beauty and makeup market saw a steady double-digit growth, with foreign high-end brands ranking higher thanks to strong brand recognition and support from Tmall 88VIP. Leading domestic brands such as Proya Cosmetics, KAFUMEI, Weina, and MAO GEPING entered the top 20 in Tmall's beauty and makeup category.
CITIC SEC released a research report stating that in the second quarter of 2026, the beauty and makeup industry is expected to continue its slow growth amidst weak demand, rising traffic costs, and increased pressure on content operations. There will be further structural differentiation, with a rebound in sales of international high-end brands and pressure on domestic mainstream and mid-range brands. MAO GEPING and FOREST CABIN are expected to continue strong growth, while GIANT BIOGENE, Yunnan Botanee Bio-Technology Group, and Harbin Fuerjia Technology are seeing a recovery in sales.
Related Articles

Jiangsu Hengrui Pharmaceuticals(600276.SH): HRS-8797 tablets obtain approval notice for clinical trials of new drugs.

Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-8829 injection concentrated solution received notification of drug clinical trial approval.

On July 14, PRU (02378) spent approximately 2.6422 million pounds to repurchase 251,800 shares.
Jiangsu Hengrui Pharmaceuticals(600276.SH): HRS-8797 tablets obtain approval notice for clinical trials of new drugs.

Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-8829 injection concentrated solution received notification of drug clinical trial approval.

On July 14, PRU (02378) spent approximately 2.6422 million pounds to repurchase 251,800 shares.

RECOMMEND





